Diabetes, and its precursor insulin resistance, is becoming increasingly common among US adults. In 2012, 29.1 million Americans had diabetes, with an estimated 7 million Americans who have undiagnosed diabetes. The average patient with new-onset type 2 diabetes actually has had it for at least 4 to 7 years before diagnosis. At the time of diagnosis, 25% have retinopathy, 9% have neuropathy, and 8% have nephropathy. These numbers are staggering but what’s even more alarming is that it is estimated that, by 2050, 1/3 of Americans will have diabetes if not controlled. At least 78 million adults age 20 and older already have prediabetes. If left uncontrolled, this can have vast implications.

COMPREHENSIVE PROTOCOL FOR INSULIN RESISTANCE AND DIABETES

Sugar and insulin control are obviously the main targets of diabetes and insulin resistance therapy. But there are lesser-known contributing factors that we should think about: mitochondrial dysfunction and estrogen balance. Our protocol for insulin resistance and diabetes addresses all three factors:

Diabend contains natural ingredients known to directly reduce blood glucose and improve pancreatic function. In particular, it has the following properties:

It can also allow muscle and fatty tissue to use and turnover glucose at its optimal rate. Typically, Diabend decreases blood sugar levels and increases insulin levels about 3 hours after a big meal but needs to be continuously used for optimal results, such as in these cases.

O.G., a 53-year-old female from Texas, is a diabetic. After taking Diabend, Myomin and OxyPower for 3 months, her glucose level reduced to 108 mg/dL.

Table 1. Chi Protocol reduced Glucose level in diabetic patient




H.B., a 59-year-old male from Texas, has diabetes and hyperlipidemia. After 3 months on Diabend, OxyPower, Myomin and Wine Extract (for cholesterol), his glucose level reduced and his cholesterol level is now within normal range. He used to go right to sleep after work. Now he has a lot more energy.

Table 2. Chi Protocol reduced Glucose Level in Male Diabetic and Hyperlipidemia patient





In both cases above, you will notice that Diabend was given in combination with OxyPower and Myomin. This ensures that diabetes is addressed from all angles.

There are various studies linking diabetes and insulin resistance to elevated estrogen levels. One study found that, among 99 patients with endometrial cancer (an estrogen-responsive type of cancer), 30 patients had diabetes. Research has revealed that exposure to environmental hormones causes insulin resistance and alteration of pancreatic beta cell function, eventually leading to diabetes.

According to Dr. Jonathan Wright, insulin resistance is present in at least 1 in 3 men with below-median serum testosterone. It is associated with hyperaromatization and estrogen excess. So if a patient has low or below-median testosterone, this is a sign of hyperaromatization and he should be tested for insulin resistance and diabetes. This is why he recommends Myomin to any men with Type II diabetes or e a family history of it.

Myomin corrects hyperaromatization of testosterone to estradiol, indirectly reducing insulin resistance. It also blocks estrogens and environmental hormones from attaching to the receptors. These environmental hormones act on receptors and modify pancreatic cell function.

OxyPower for Improving Mitochondrial DNA Function for Diabetes and Insulin Resistance

Diabetes and insulin resistance are associated with DNA damage and mitochondrial dysfunction caused by oxidative stress. OxyPower has been demonstrated to significantly reduce oxidative stress and improve mitochondrial efficacy, allowing better utilization of oxygen and glucose in cells. It reduces oxidative damage by increasing the cell protective markers, superoxide dismutase and glutathione, while reducing malondialdehyde, a lipid peroxide product that contributes to cell damage.

This mechanism enables OxyPower to be beneficial for individuals with neuropathy, a complication of diabetes that affects peripheral nerves. This was seen in a study involving 59 diabetic patients with tingling hands and feet, a common symptom of neuropathy. After 3 months of taking OxyPower, the symptom was completely eliminated in 66.1% of the patients.

The following case reports show that the combination of Diabend, Myomin and OxyPower has proven to be effective in controlling blood glucose as well as hemoglobin A1c (HbA1c), which measures the average blood glucose over a period of 3 months.

A 74-year-old diabetic patient has been taking prescription Gliquidone but his HbA1c was still elevated at 7.6 (should be < 5.7). After taking OxyPower and Myomin, his level decreased.

Table 3. Oxypower and Myomin reduced HbA1c after 6 months

A 69-year-old female from New York had an elevated HbA1c level at 5.9. A year later, it further increased to 6.0. Soon after that, she started taking Diabend, OxyPower, and Myomin. After 5 months, her HbA1c level reduced by 5%.

Table 4. Chi Protocol reduced HbA1c in Female patient after 5 months